• For Individuals
  • For Institutions
  • Download
  • Help

  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文（廣東話）Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials

Event Tracking

Nov19
EyePoint Pharmaceuticals' DURAVYU Phase 3 Clinical Trial for Wet AMD Receives Positive Safety Review
12:06
Nov10
Mizuho Securities Maintains Buy Rating on EyePoint Pharmaceuticals
13:57
Nov7
JonesTrading Analyst Reiterates Buy Rating on EyePoint Pharmaceuticals
02:38
Nov5
EyePoint Pharmaceuticals Reports Progress on Lead Project DURAVYU, Anticipates Top-Line Phase 3 Data in Mid-2026
19:46
TD Cowen Reiterates Buy Rating With a Target Price of $20.00
17:02
Eyepoint Pharmaceuticals released FY2025 9 months earnings on November 5 Pre-Market (EST), actual revenue USD 30.75M, actual EPS USD -2.3489
14:30

Schedules & Filings

Schedules
Filings
Nov5
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 966 K, Net Income -59.73 M, EPS -0.8512

Aug6
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 5.333 M, Net Income -59.43 M, EPS -0.8498

May7
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 24.45 M, Net Income -45.2 M, EPS -0.6477

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
WSHP
200.000
+506.06%
+167.000
SGBX
6.070
+78.01%
+2.660
BACCR
0.3900
+77.27%
+0.170
SEMR
11.760
+73.96%
+5.000
PGACR
0.3500
+59.02%
+0.130
NUVB
7.150
+48.96%
+2.350
SSEAR
0.2999
+42.81%
+0.090
HXHX
0.7879
+41.15%
+0.230
CABR
1.090
+39.96%
+0.311
STEC
1.050
+38.82%
+0.294
View More
Terms & Conditions
  • Terms of Service
  • Privacy Policy